BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 104 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 0.44 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,130,124 | +20.4% | 182,868 | -1.0% | 0.00% | +100.0% |
Q1 2024 | $938,723 | -21.6% | 184,788 | -7.6% | 0.00% | -50.0% |
Q4 2023 | $1,197,766 | -19.0% | 199,961 | -4.2% | 0.00% | 0.0% |
Q3 2023 | $1,478,134 | -8.3% | 208,776 | -8.8% | 0.00% | 0.0% |
Q2 2023 | $1,611,301 | -17.0% | 228,878 | -1.7% | 0.00% | -33.3% |
Q1 2023 | $1,941,410 | -28.3% | 232,783 | -1.3% | 0.00% | -25.0% |
Q4 2022 | $2,707,558 | -7.7% | 235,850 | +1.2% | 0.00% | -20.0% |
Q3 2022 | $2,935,000 | +17.1% | 232,969 | -1.7% | 0.01% | +25.0% |
Q2 2022 | $2,506,000 | -33.2% | 236,885 | +2.6% | 0.00% | -20.0% |
Q1 2022 | $3,753,000 | +8.8% | 230,808 | -7.3% | 0.01% | +25.0% |
Q4 2021 | $3,450,000 | -0.8% | 249,091 | +2.9% | 0.00% | 0.0% |
Q3 2021 | $3,479,000 | -10.2% | 242,118 | -1.2% | 0.00% | -20.0% |
Q2 2021 | $3,874,000 | +43.0% | 245,054 | -8.0% | 0.01% | +25.0% |
Q1 2021 | $2,709,000 | +36.0% | 266,359 | -0.4% | 0.00% | +33.3% |
Q4 2020 | $1,992,000 | +117.0% | 267,344 | 0.0% | 0.00% | +200.0% |
Q3 2020 | $918,000 | -17.7% | 267,344 | +14.2% | 0.00% | -50.0% |
Q2 2020 | $1,115,000 | +143.4% | 234,035 | +2.3% | 0.00% | +100.0% |
Q1 2020 | $458,000 | -41.3% | 228,854 | +1.2% | 0.00% | 0.0% |
Q4 2019 | $780,000 | +58.5% | 226,217 | +31.8% | 0.00% | 0.0% |
Q3 2019 | $492,000 | -22.9% | 171,591 | +2.0% | 0.00% | 0.0% |
Q2 2019 | $638,000 | -53.4% | 168,289 | 0.0% | 0.00% | -66.7% |
Q1 2019 | $1,370,000 | -4.9% | 168,289 | -5.7% | 0.00% | 0.0% |
Q4 2018 | $1,440,000 | +13.0% | 178,440 | +6.9% | 0.00% | +50.0% |
Q3 2018 | $1,274,000 | +47.5% | 166,932 | +10.8% | 0.00% | 0.0% |
Q2 2018 | $864,000 | +21.3% | 150,708 | +1.0% | 0.00% | 0.0% |
Q1 2018 | $712,000 | -6.1% | 149,223 | -3.4% | 0.00% | 0.0% |
Q4 2017 | $758,000 | +13.0% | 154,455 | +20.6% | 0.00% | +100.0% |
Q3 2017 | $671,000 | -15.0% | 128,045 | -9.8% | 0.00% | -50.0% |
Q2 2017 | $789,000 | -40.3% | 141,883 | -9.8% | 0.00% | -33.3% |
Q1 2017 | $1,322,000 | +38.1% | 157,383 | +4.1% | 0.00% | +50.0% |
Q4 2016 | $957,000 | +39.5% | 151,183 | -2.8% | 0.00% | +100.0% |
Q3 2016 | $686,000 | +56.6% | 155,483 | +0.9% | 0.00% | 0.0% |
Q2 2016 | $438,000 | +0.7% | 154,083 | +0.3% | 0.00% | 0.0% |
Q1 2016 | $435,000 | -68.6% | 153,583 | +14.3% | 0.00% | -66.7% |
Q4 2015 | $1,387,000 | -7.8% | 134,426 | +1.8% | 0.00% | -25.0% |
Q3 2015 | $1,505,000 | -23.9% | 132,050 | -0.3% | 0.00% | -20.0% |
Q2 2015 | $1,977,000 | +71.2% | 132,450 | +3.6% | 0.01% | +66.7% |
Q1 2015 | $1,155,000 | -26.8% | 127,887 | -1.5% | 0.00% | -25.0% |
Q4 2014 | $1,578,000 | +24.8% | 129,787 | +0.4% | 0.00% | +33.3% |
Q3 2014 | $1,264,000 | -22.5% | 129,234 | +1.0% | 0.00% | -25.0% |
Q2 2014 | $1,631,000 | +1514.9% | 127,900 | +50.0% | 0.00% | – |
Q1 2013 | $101,000 | – | 85,258 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $40,692,000 | 16.07% |
Fairmount Funds Management LLC | 3,343,107 | $35,370,000 | 8.10% |
Kynam Capital Management, LP | 936,563 | $9,909,000 | 2.53% |
Velan Capital Investment Management LP | 225,000 | $2,381,000 | 2.42% |
ORACLE INVESTMENT MANAGEMENT INC | 603,994 | $6,390,000 | 1.94% |
TANG CAPITAL MANAGEMENT LLC | 1,200,000 | $12,696,000 | 1.93% |
MPM BioImpact LLC | 639,089 | $6,762,000 | 1.88% |
Ghost Tree Capital, LLC | 325,000 | $3,439,000 | 1.79% |
Sarissa Capital Management LP | 1,390,790 | $14,715,000 | 1.48% |
Prosight Management, LP | 176,680 | $1,869,000 | 1.47% |